Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer

被引：0
作者：
Kraeber-Bodere, F. [1 ,2 ]
Goldenberg, D. M. [3 ]
Chatal, J. F. [4 ]
Barbet, J. [2 ,4 ]
机构：
[1] Univ Hosp, Dept Nucl Med, Nantes, France
[2] Univ Nantes, INSERM, Canc Res Ctr, Nantes, France
[3] Ctr Mol Med & Immunol, Garden State Canc Ctr, Belleville, NJ USA
[4] Univ Nantes, Arronax Cyclotron, Nantes, France
来源：
CURRENT ONCOLOGY | 2009年 / 16卷 / 05期
关键词：
Pretargeted radioimmunotherapy; medullary thyroid cancer; calcitonin; BISPECIFIC ANTIBODY; PROGNOSTIC-FACTORS; BIVALENT HAPTEN; IMATINIB MESYLATE; FOLLOW-UP; CARCINOMA; SURVIVAL; CHEMOEMBOLIZATION; OPTIMIZATION; CALCITONIN;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：296 / 301
页数：6
相关论文
共 35 条
[1]   Pretargeting with the Affinity Enhancement System for radioimmunotherapy [J].
Barbet, J ;
Kraeber-Bodéré, F ;
Vuillez, JP ;
Gautherot, E ;
Rouvier, R ;
Chatal, JF .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (03) :153-166
[2]   Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma [J].
Barbet, J ;
Campion, L ;
Kraeber-Bodéré, F ;
Chatal, JF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :6077-6084
[3]  
Bardies M, 1996, J NUCL MED, V37, P1853
[4]  
Bergholm U, 1997, CANCER-AM CANCER SOC, V79, P132, DOI 10.1002/(SICI)1097-0142(19970101)79:1<132::AID-CNCR19>3.0.CO
[5]  
2-5
[6]   PROGNOSTIC INDEX FOR THYROID-CARCINOMA - STUDY OF THE EORTC-THYROID-CANCER-COOPERATIVE-GROUP [J].
BYAR, DP ;
GREEN, SB ;
DOR, P ;
WILLIAMS, ED ;
COLON, J ;
VANGILSE, HA ;
MAYER, M ;
SYLVESTER, RJ ;
VANGLABBEKE, M .
EUROPEAN JOURNAL OF CANCER, 1979, 15 (08) :1033-1041
[7]   Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy:: A collaborative study with the French Endocrine Tumor Group [J].
Chatal, JF ;
Campion, L ;
Kraeber-Bodéré, F ;
Bardet, S ;
Vuillez, JP ;
Charbonnel, B ;
Rohmer, V ;
Chang, CH ;
Sharkey, RM ;
Goldenberg, DM ;
Barbet, J .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (11) :1705-1711
[8]  
COHEN EE, 2007, P AM SOC CLIN ONCOL, V25
[9]   A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma [J].
de Groot, J. W. B. ;
Zonnenberg, B. A. ;
van Ufford-Mannesse, P. Quarles ;
de Vries, M. M. ;
Links, T. P. ;
Lips, C. J. M. ;
Voest, E. E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09) :3466-3469
[10]   Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:: A 10-year follow-up study [J].
Elisei, Rossella ;
Cosci, Barbara ;
Romei, Cristina ;
Bottici, Valeria ;
Renzini, Giulia ;
Molinaro, Eleonora ;
Agate, Laura ;
Vivaldi, Agnese ;
Faviana, Pinuccia ;
Basolo, Fulvio ;
Miccoli, Paolo ;
Berti, Piero ;
Pacini, Furio ;
Pinchera, Aldo .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (03) :682-687
1234